Clinical trial
A Trial of 2 Options for Second Line Combination Antiretroviral Therapy…
NCT00931463 · Kirby Institute, Other · Completed
Key facts
| NCT number | NCT00931463 |
|---|---|
| Title | A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen |
| Official title | A Randomised Open-label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-line NNRTI/2N(t)RTI Therapy |
| Acronym | SECOND-LINE |
| Lead sponsor | Kirby Institute, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry Abbott amfAR, The Foundation for AIDS Research |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | raltegravir, 2N(t)RTI, Ritonavir-boosted lopinavir |
| Enrollment | 558 |
| Start date | Sep 1, 2009 |
| Primary completion | Sep 1, 2012 |
| Completion | Aug 1, 2013 |
| First posted | Jul 2, 2009 |
| Last update posted | Sep 4, 2019 |
| Countries | Argentina, Australia, Chile, France, Germany, Hong Kong, India, Ireland, Malaysia, Mexico, New Zealand, Nigeria and 5 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: